mArkEtnEws2DAy.Com
monDAy, oCtoBEr 17, 15:52
BrEAking nEws....BrEAking nEws....BrEAking nEws
shArEs inBrussEls-BAsED rosCoE phArmACEutiCAlsCo. rosE shArply toDAy on hEAvy trADing. thE risE CAmE AFtErCEo lEonArDBouvEiEr rEvEAlED thAt FinAl tEsts oF A nEw Drug For olDEr pAtiEnts, thosE BEtwEEn 65 AnD 80, hAD provED morE suCCEssFul thAn hopED、
thE Drug, CAllED horizon h54, is AimED At AiDing mEmory. tEst rEsults showED thAt it CoulD slow mEmory loss By As muCh As 17% in pAtiEnts iF tAkEn rEgulArly AnD in ComBinAtion with othEr prEsCriBED mEDiCAtion.CEoBouvEiEr sAiD thE CompAny hopED to lAunCh thE Drug By jAnuAry oF nExt yEAr AFtEr thE CurrEnt ApprovAl proCEss By govErnmEnt rEgulAtors is ComplEtED、
AnAlysts hAvE vAluED thE potEntiAl mArkEt vAluE For thE Drug inEuropE AnD northAmEriCA At ArounD
Billion.
thE nEws mEAns rosCoE hAs now gottEn AhEAD oF its ClosEst CompEtitor, lonDon-BAsEDDEvitt hEAlth group, in this FiElD、DEvitt is known to hAvE BEEn working on A similAr Drug For thE pAst EightEEn months.
whAt is thE CurrEnt stAtus oF horizon h54
A、it is BEing ComBinED with othEr mEDiCinEs.
B、it is BEing prEsCriBED in hospitAls.
C、it is BEing AnAlyzED By oFFiCiAls.
D、it is BEing mArkEtED through sAlEs groups.